	US 12,187,787 B2
	Antibacterial antibody and use thereof
Hyung Joo Kwon, Cheongju-Si (KR); Te Ha Kim, Chuncheon-Si (KR); and Dong Bum Kim, Chuncheon-Si (KR)
Assigned to INDUSTRY ACADEMIC COOPERATION FOUNDATION, HALLYM UNIVERSITY, Chuncheon-Si (KR)
Appl. No. 16/982,575
Filed by INDUSTRY ACADEMIC COOPERATION FOUNDATION, HALLYM UNIVERSITY, Chuncheon-Si (KR)
PCT Filed Feb. 26, 2019, PCT No. PCT/KR2019/002302 § 371(c)(1), (2) Date Sep. 20, 2020, PCT Pub. No. WO2019/182257, PCT Pub. Date Sep. 26, 2019.
Claims priority of application No. 10-2018-0033849 (KR), filed on Mar. 23, 2018.
Prior Publication US 2021/0017258 A1, Jan. 21, 2021
Int. Cl. C07K 16/12 (2006.01); A61K 39/00 (2006.01); A61P 31/04 (2006.01)

CPC C07K 16/1271 (2013.01) [A61K 39/00 (2013.01); A61P 31/04 (2018.01); C07K 16/12 (2013.01); C07K 16/1232 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01)]

5 Claims

1. A monoclonal antibody specifically binding to S. aureus NW2, said monoclonal antibody comprising:

a heavy chain comprising a complementarity determining region 1 (CDR 1) amino acid sequence consisting of the sequence of SEQ ID NO: 1, a CDR2 consisting of the sequence of SEQ ID NO: 2 and a CDR 3 consisting of the sequence of SEQ ID NO: 3; and

a light chain comprising CDR1 amino acid sequence consisting of the sequence of SEQ ID NO: 4, a CDR2 consisting of the sequence of SEQ ID NO: 5 and a CDR 3 consisting of the sequence of SEQ ID NO: 6.